Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1979 1
1989 1
1990 1
1994 1
1998 1
2000 1
2001 1
2002 3
2003 4
2004 2
2005 4
2006 3
2007 4
2008 5
2009 1
2010 6
2011 2
2012 4
2013 5
2014 4
2015 4
2016 3
2017 4
2018 7
2019 7
2020 6
2021 6
2022 3
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management.
Susanibar-Adaniya S, Barta SK. Susanibar-Adaniya S, et al. Am J Hematol. 2021 May 1;96(5):617-629. doi: 10.1002/ajh.26151. Epub 2021 Mar 19. Am J Hematol. 2021. PMID: 33661537 Free PMC article. Review.
Diffuse large B cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL), comprises a heterogeneous group of diseases with different biology, clinical presentations, and response to treatment. ...Advances on the un
Diffuse large B cell lymphoma (DLBCL), the most common type of Non-Hodgkin lymphoma (NHL),
Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment.
Liu Y, Barta SK. Liu Y, et al. Am J Hematol. 2019 May;94(5):604-616. doi: 10.1002/ajh.25460. Am J Hematol. 2019. PMID: 30859597 Free article. Review.
DISEASE OVERVIEW: Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non-Hodgkin lymphoma originating from the germinal center, and it represents a heterogeneous group of diseases with variable outcomes tha …
DISEASE OVERVIEW: Diffuse large B-cell lymphoma (DLBCL) is the most common type of aggressive non- …
Diffuse large B-cell lymphoma.
Li S, Young KH, Medeiros LJ. Li S, et al. Pathology. 2018 Jan;50(1):74-87. doi: 10.1016/j.pathol.2017.09.006. Epub 2017 Nov 20. Pathology. 2018. PMID: 29167021 Review.
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide, representing approximately 30-40% of all cases in different geographic regions. ...The most popular system divides cases of DLBCL acco
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma world
Regulation of the MIR155 host gene in physiological and pathological processes.
Elton TS, Selemon H, Elton SM, Parinandi NL. Elton TS, et al. Gene. 2013 Dec 10;532(1):1-12. doi: 10.1016/j.gene.2012.12.009. Epub 2012 Dec 14. Gene. 2013. PMID: 23246696 Review.
MicroRNAs (miRNAs), a family of small nonprotein-coding RNAs, play a critical role in posttranscriptional gene regulation by acting as adaptors for the miRNA-induced silencing complex to inhibit gene expression by targeting mRNAs for translational repression and/or cleavage. miR- …
MicroRNAs (miRNAs), a family of small nonprotein-coding RNAs, play a critical role in posttranscriptional gene regulation by acting as adapt …
Precision medicine for human cancers with Notch signaling dysregulation (Review).
Katoh M, Katoh M. Katoh M, et al. Int J Mol Med. 2020 Feb;45(2):279-297. doi: 10.3892/ijmm.2019.4418. Epub 2019 Dec 4. Int J Mol Med. 2020. PMID: 31894255 Free PMC article. Review.
Notch signaling is aberrantly activated in breast cancer, non-small-cell lung cancer and hematological malignancies, such as T-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma. ...ADCs and CAR-Ts could alter the therape …
Notch signaling is aberrantly activated in breast cancer, non-small-cell lung cancer and hematological malignancies, such as T-cell a …
Full-length recombinant antibodies from Escherichia coli: production, characterization, effector function (Fc) engineering, and clinical evaluation.
Rashid MH. Rashid MH. MAbs. 2022 Jan-Dec;14(1):2111748. doi: 10.1080/19420862.2022.2111748. MAbs. 2022. PMID: 36018829 Free PMC article. Review.
This review summarizes recent research, preclinical advancements, and clinical development of E. coli-produced aglycosylated therapeutic antibodies as monoclonal, bispecific, and antibody-drug conjugates for use in autoimmune, oncology, and immuno-oncology areas.Abbreviations: AD …
This review summarizes recent research, preclinical advancements, and clinical development of E. coli-produced aglycosylated therapeutic ant …
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chang S, Yim S, Park H. Chang S, et al. Exp Mol Med. 2019 Jun 20;51(6):1-17. doi: 10.1038/s12276-019-0230-6. Exp Mol Med. 2019. PMID: 31221981 Free PMC article. Review.
We have also discussed mutations in other isoforms such as the JARID1A, 1B, 1D of KDM5 subfamilies and the JMJD3/KDM6B of KDM6 subfamilies, which play opposing roles in tumor progression as oncogenes or tumor suppressors depending on the cancer cell type. Table 1 Cancer dr …
We have also discussed mutations in other isoforms such as the JARID1A, 1B, 1D of KDM5 subfamilies and the JMJD3/KDM6B of KDM6 subfamilies, …
Genetic and epigenetic determinants of diffuse large B-cell lymphoma.
Bakhshi TJ, Georgel PT. Bakhshi TJ, et al. Blood Cancer J. 2020 Dec 4;10(12):123. doi: 10.1038/s41408-020-00389-w. Blood Cancer J. 2020. PMID: 33277464 Free PMC article. Review.
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma and is notorious for its heterogeneity, aggressive nature, and the frequent development of resistance and/or relapse after treatment with standard chemothera
Diffuse large B-cell lymphoma (DLBCL) is the most common type of lymphoma and is notorious
Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma.
Sun F, Fang X, Wang X. Sun F, et al. Anticancer Agents Med Chem. 2019;19(17):2047-2059. doi: 10.2174/1871520619666190925143216. Anticancer Agents Med Chem. 2019. PMID: 32009599 Review.
BACKGROUND: Diffuse Large B Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma which is heterogeneous both clinically and morphologically. ...OBJECTIVE: The current review aims to present a brief overview of sign …
BACKGROUND: Diffuse Large B Cell Lymphoma (DLBCL) is the most common type of non-Hodgkin lympho
Advances in Diagnosis and Management of Diffuse Large B-cell Lymphoma.
Cabanillas F, Shah B. Cabanillas F, et al. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):783-796. doi: 10.1016/j.clml.2017.10.007. Epub 2017 Nov 7. Clin Lymphoma Myeloma Leuk. 2017. PMID: 29126866 Review.
The management of diffuse large B-cell lymphoma (DLBCL) has been gradually evolving since the discovery of its 2 major forms, the germinal center B-like (GCB) and activated B-cell (ABC) types. ...We also discuss the front-li …
The management of diffuse large B-cell lymphoma (DLBCL) has been gradually evolving since the discovery o …
88 results